Camptothecin Derivatives Reducing Protein Binding and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Camptothecin derivatives exhibit high toxicity and poor solubility, limiting their therapeutic efficacy due to high protein binding and lipophilicity, which affects tissue distribution and accumulation in tumors, necessitating the development of low protein binding and highly potent compounds with improved solubility.
Innovation Solution
Design and synthesis of camptothecin derivatives with specific modifications at the 5-, 7-, 9-, and 11-positions, including the conversion of pyridone rings to thiopyridone, to reduce protein binding and enhance solubility, while maintaining stability and antitumor activity, as exemplified by compounds of general formula I, which show low protein binding and high potency even at low doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives are used for antitumor therapy, then high topoisomerase inhibition activity is achieved, but high toxicity occurs (hemorrhagic cystitis, gastrointestinal toxicity, myelosuppression)
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions (5-, 7-, 9-, 11-) of the camptothecin molecule. Each substitution modifies local chemical properties to reduce systemic toxicity while preserving the core topoisomerase inhibition mechanism. For example, introducing hydrophilic groups at position 5 reduces hemorrhagic cystitis without affecting DNA-Topoisomerase I binding.
Solution Approach 2:
The patent systematically changes chemical parameters of camptothecin derivatives including substituent types (alkyl, alkoxy, aminoalkyl, hydroxyalkyl), positions of substitution (5-, 7-, 9-, 11-), and stereochemistry (20S configuration). These parameter changes optimize the balance between antitumor efficacy and toxicity profile, producing compounds with improved therapeutic indices.
2Reliability
If camptothecin derivatives are administered, then antitumor effect is achieved, but poor solubility limits therapeutic efficacy
Solution Approach 1:
The patent changes physical-chemical parameters by introducing hydrophilic substituents (hydroxyalkyl, alkoxy, aminoalkyl groups with 1-8 carbon atoms) at positions 5, 7, 9, and 11. These modifications increase water solubility while maintaining the lactone ring integrity and topoisomerase inhibition capability, enabling better pharmacokinetic properties and therapeutic efficacy.
3Reliability
If camptothecin derivatives are administered, then topoisomerase inhibition is achieved, but high protein binding reduces tissue distribution to tumors
Solution Approach 1:
The patent applies local quality by strategically placing substituents at specific positions to modulate protein binding characteristics. The 5-position substitution with hydrophilic groups reduces albumin binding affinity, while the 7- and 9-position substitutions maintain DNA-Topoisomerase I interaction. This selective modification improves tumor tissue distribution without compromising mechanism of action.
4Reliability
If modifications are made at 5-, 7-, 9-, and 11-positions to reduce protein binding and improve solubility, then therapeutic efficacy is improved, but stability of DNA-Topoisomerase I-camptothecin ternary complex must be maintained
Solution Approach 1:
The patent applies local quality by making selective substitutions at positions 5, 7, 9, and 11 that do not interfere with the critical DNA-Topoisomerase I-binding interface. The modifications are placed in regions that affect solubility and protein binding but not the core ternary complex stability, preserving antitumor mechanism while improving pharmacological properties.
Solution Approach 2:
The patent changes chemical parameters (substituent type, position, stereochemistry) to optimize the balance between ternary complex stability and pharmacological properties. The 20S configuration and specific substituent patterns are selected to maintain DNA binding affinity while reducing off-target effects and improving solubility.
Data Source
AI summary
Novel camptothecin derivatives of Formula (I) having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.